According to CMS, the MEDCAC panel will consider the evidence about molecular pathology tests that estimate the prognosis of several frequently encountered types of cancer, including:
- Adenocarcinoma of the colon and rectum;
- Invasive breast cancer; and
- Non-small cell lung cancer.
“Payers are demanding better evidence in the molecular pathology space as the technology becomes more available,” said Dan Mendelson, CEO of Avalere. “Lakshman brings deep content expertise and experience to the panel, having worn relevant hats in both the public and private sectors.”
Lakshman is a well-known expert on medical device regulation. Prior to joining Avalere, Lakshman worked at the Food and Drug Administration’s Center for Devices and Radiological Health as senior reviewer, leading the FDA-CMS Parallel Review pilot project, and later as policy advisor and acting associate director. Previously, Lakshman served as a bioinformatics specialist at GlaxoSmithKine and a genomics manager at Almac Diagnostics, Inc. He has a PhD in Molecular Biology from the University of North Carolina at Chapel Hill.